NCT02182661已完成3 期
A Phase III Long-term Study of Ba253BINEB in Patients With Bronchial Asthma
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 88
- 主要终点
- Number of patients with adverse events
研究概览
简要总结
The objective of this study is to investigate the long-term safety of Ba253BINEB. Secondarily the long-term efficacy of Ba253BINEB is also investigated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patients with bronchial asthma and who satisfy the following criteria
- •Patients aged >= 20 years or older
- •Patients with mild to moderate severity
- •Patients must be able to understand the patient information form
排除标准
- •Patients who have taken an long acting corticosteroids(i.m.) within 1 month before the screening test
- •Patients using corticosteroid medication( p.o./ i.h.) at a dose in excess of the equivalent 10 mg/day of prednisolone
- •Patients with glaucoma
- •Patients who have prostatic hypertrophy
- •Patients with hypersensitivity to anticholinergic drugs
- •Patients who began treatment with hyposensitization or immunoregulator therapy within 3 month before the screening test
- •Patients complicated with chronic bronchitis, emphysema or bronchiectasis, making the assessment of drug efficacy against bronchial asthma difficult
- •Patients with serious hepatic disease, kidney disease or heart disorder and who are judged by the investigator as inappropriate as the subjects of study
- •Women who are pregnant or who may become pregnant, or nursing women
- •Patients who are judged by the investigator as inappropriate as the subjects of the study
研究组 & 干预措施
Ba253BINEB
Experimental
干预措施: Ba253BINEB (Drug)
结局指标
主要结局
Number of patients with adverse events
时间窗: 30 weeks
Number of patients with abnormal changes in blood pressure and heart rate
时间窗: Baseline, up to 28 weeks
Number of patients with abnormal changes in ECG (electrocardiogram)
时间窗: Baseline, up to 28 weeks
Number of patients with abnormal changes in laboratory parameters
时间窗: Baseline, up to 28 weeks
次要结局
- Change from baseline in symptom score(Baseline, up to 28 weeks)
- Change from baseline in treatment score(Baseline, up to 28 weeks)
- Change from baseline in asthma score(Baseline, week 28)
- Change from baseline in daily life score(Baseline, up to 28 weeks)
- Change from baseline in nocturnal sleep score(Baseline, up to 28 weeks)
- Change from baseline in Peak expiratory flow rate (PEFR)(Baseline, up to 28 weeks)
- Physician's global evaluation (overall improvement and final overall improvement)(Baseline, up to 28 weeks)
- Patient's impression(Week 28)
- Change from baseline in FEV1 (Forced expiratory volume in one second)(Baseline, up to 28 weeks)
- Change from baseline in FVC (Forced vital capacity)(Baseline, up to 28 weeks)
研究者
相似试验
已完成
3 期
Ba253BINEB in Patients With Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT02182635Boehringer Ingelheim74
已完成
3 期
Ba253BINEB Compared to Ba253MDI (Metered Dose Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT02182583Boehringer Ingelheim163
终止
2 期
BIIB023 Long-Term Extension Study in Subjects With Lupus NephritisLupus NephritisNCT01930890Biogen87
终止
3 期
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease PatientsAlzheimer DiseaseNCT00998764Pfizer494
已完成
3 期
An Extension Study in Participants With Moderate to Severe Rheumatoid ArthritisRheumatoid ArthritisNCT01885078Eli Lilly and Company2,877